Purpose {#sec1}
=======

The radical treatment for locally advanced cervical cancer consists of radiotherapy with concurrent chemotherapy \[[@cit0001]\]. Pelvic brachytherapy following external beam radiotherapy is an effective way to maximize radiation dose to the tumor, while limiting dose to adjacent normal organs. 3D (three dimensional) brachytherapy planning has been introduced in the Western population for more than a decade to allow precision in localization of treatment targets and organs at risk. RetroEMBRACE, a retrospective multi-institutional observational study, has shown that magnetic resonance imaging (MRI)-based or computed tomography (CT)-based brachytherapy shows favorable local, pelvic control, and overall survival compared with 2D technique, with excellent toxicity profile \[[@cit0002]\].

MRI shows superior soft tissue delineation compared with CT, and has become the gold standard for image-guided brachytherapy (IGBT) in European countries \[[@cit0003]\]. Tumor dose-effect relationship has been well demonstrated in MRI-based brachytherapy \[[@cit0004]\]. However, routine use of MRI-guided brachytherapy remains a challenge in terms of time and financial costs, especially in regions with high incidence of the disease such as Asia \[[@cit0005]\].

Past studies have shown that CT-delineated HRCTV (HRCTV~ct~) is statistically different from MRI-delineated HRCTV (HRCTV~mri~)~,~ even with pre-planning MRI \[[@cit0003], [@cit0006], [@cit0007], [@cit0008], [@cit0009], [@cit0010]\]. Such volumetric difference has translated into change in HRCTV D~90~, while dose to OAR show no statistical difference. Viswanathan *et al*. proved that HRCTV~ct~ D~90~ in CT-based plans is statistically lower than HRCTV~mri~ D~90~ in MRI guided plans, with mean dose per fraction of 6.7 Gy vs. 8.7 Gy, respectively \[[@cit0003]\]. Bhavana *et al*. showed similar findings, with the mean difference in dose per fraction less than 1 Gy \[[@cit0008]\].

However, regardless of the planning modality, it is the dose to the 'actual' targets as delineated based on MRI that is more of clinical relevance \[[@cit0004]\] yet infrequently reported. Despite the fact that the D~90~ of HRCTV~ct~ tends to be lower in CT-based plans compared with HRCTV~mri~ D~90~ of MRI-based plans, the 'actual' HRCTV of concern i.e., HRCTV~mri~ may fall into the high dose zone of CT plans. As a result, CT planning may result in similar dose delivered to the 'actual target'. On the other hand, further boost to the 'actual' HRCTV by MRI-based planning may be limited by the position of the adjacent organs at risk, which are just as clearly shown on CT compared with MRI \[[@cit0003]\]. The aim of this study is to compare the dose received by the 'actual' targets and organs at risk between CT- and MRI-based planning, in order to determine whether CT is an economical alternative to MRI in IGBT.

Material and methods {#sec2}
====================

Treatment overview {#sec2.1}
------------------

Patients with biopsy proven cervical carcinoma with MRI-based IGBT performed between 1^st^ January 2016 and 28^th^ February 2017 were reviewed. All patients had undergone clinical gynecological examination and diagnostic MRI pelvis. They received radiotherapy with concurrent weekly cisplatin. External whole pelvic irradiation (WPI) using intensity-modulated radiation therapy (IMRT) technique (45 Gy in 25 fractions, 5 fractions per week) was planned with reference to the RTOG consensus guidelines \[[@cit0011], [@cit0012]\]. For patients with para-aortic lymph node metastases, extended field IMRT with simultaneous intermittent boost (SIB) of 2.2 to 2.3 Gy per fraction was given to the involved lymph nodes \[[@cit0013]\]. After external radiotherapy, 4 fractions of high-dose-rate ^192^Ir brachytherapy were performed. Additional parametrial boost (API) was planned after the first fraction of brachytherapy.

3D brachytherapy for cervical cancer with MRI-planning {#sec2.2}
------------------------------------------------------

MRI guided IGBT with 'hybrid' technique was adopted \[[@cit0014]\]. At week 5, pre-planning MRI pelvis was performed without applicator in-situ to assist treatment planning. Four fractions of brachytherapy were given in 2 weeks, with 2 fractions given on 2 consecutive days per week, leaving the applicator in-situ overnight after the first fraction of each week. Planning was done under the guidance of a pre-brachytherapy MRI with applicator in-situ during the first fraction, while CT-based planning was performed in each of the 3 remaining fractions with fused MRI contours. Adjustments were made based on change in anatomical positions of OAR. Contouring was performed according to the GEC-ESTRO (Groupe Européen de Curiethérapie European Society for Radiotherapy and Oncology) recommendations on the planning images, with reference to the gynecological examination findings at diagnosis and during brachytherapy, diagnostic and week 5 pre-planning MRI \[[@cit0015], [@cit0016]\]. Plan was optimized by medical physicist using Oncentra BrachyTreatment Planning System version 4.5.2 (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden). A pre-brachytherapy CT was also done immediately after MRI during the first fraction.

Details of pre-planning MRI, pre-brachytherapy MRI, and pre-brachytherapy CT {#sec2.3}
----------------------------------------------------------------------------

MRI images were performed using a whole-body MRI system (Philips Achieva 3.0TX, Philips Healthcare, Best, The Netherlands) with 6 channel cardiac coil, with section thickness of 3 mm without intersection gap. Para-axial, para-coronal, and para-sagittal images were performed according to the alignment of uterus for week 5 pre-planning MRI, and according to the axis of applicator for the pre-brachytherapy MRI. For pre-planning MRI, plain T1- and T2-weighted, with or without gadolinium contrast T1-weighted images were done. For pre-brachytherapy MRI, only T2-weighted plain images were performed \[[@cit0017]\]. For pre-brachytherapy CT, plain images were performed with 1.5 mm cut. Pre-brachytherapy CT was done within 30 minutes after pre-brachytherapy MRI.

Planning aims and constraints {#sec2.4}
-----------------------------

Planning aims and constraints are listed in [Table 1](#t0001){ref-type="table"}. They were derived based on the assumption that roughly the same dose was to be delivered per fraction. The planning constraints were set with reference to the EMBRACE protocol and the book "Gynecologic Radiation Therapy" \[[@cit0018]\], whereas the planning aims were similar to the updated EMBRACE II protocol, with adjustments based on retroEMBRACE and EMBRACE studies results \[[@cit0002], [@cit0004], [@cit0019]\] (<https://www.embracestudy.dk/>) from January to May 2016, only the planning constraints were followed. Planning aims were added since June 2016 in MRI-based planning. HRCTV D~90~ of ≥ 85 Gy and IRCTV D~90~ of ≥ 65 Gy in total correspond to 3-year local control rates of \> 86% \[[@cit0004]\].

###### 

Planning aims and constraints

  Parameters       Planning aim, dose per fraction (Gy)   Planning aim, total dose (Gy)           Planning constraint, dose per fraction (Gy)   Planning constraint, total dose (Gy)
  ---------------- -------------------------------------- --------------------------------------- --------------------------------------------- -----------------------------------------
  HRCTV D~90~      ≥ 7.8                                  ≥ 90                                    ≥ 7.2                                         ≥ 85
  IRCTV D~90~      ≥ 4.4                                  ≥ 65                                    ≥ 3.5                                         ≥ 60
  Bladder D~2cc~   ≤ 5.4                                  ≤ 80[\*](#tf1-1){ref-type="table-fn"}   ≤ 6.2                                         ≤ 90[^\#^](#tf1-2){ref-type="table-fn"}
  Rectum D~2cc~    ≤ 3.9                                  ≤ 65[\*](#tf1-1){ref-type="table-fn"}   ≤ 4.9                                         ≤ 75[^\#^](#tf1-2){ref-type="table-fn"}
  Sigmoid D~2cc~   ≤ 4.4                                  ≤ 70[\*](#tf1-1){ref-type="table-fn"}   ≤ 4.9                                         ≤ 75[^\#^](#tf1-2){ref-type="table-fn"}

HRCTV, IRCTV -- high-risk and low-risk clinical target volume, D~90~ -- the percentage of the prescribed dose received by 90% volume of the prostate, D~2cc~ -- minimum dose to the most exposed 2 cm^3^

With reference to EMBRACE II protocol

With reference to EMBRACE protocol

Data analysis {#sec2.5}
-------------

The first fraction of IGBT was evaluated. The pre-brachytherapy CT at first IGBT was contoured with reference to clinical examination at diagnosis and during the first IGBT, MRI at diagnosis, and a week 5 pre-planning MRI. CT contouring guidelines was referred \[[@cit0007]\]. There was no fusion of any MRI images to planning CT. Graphically optimized CT-based plan was generated by medical physicist based on planning aims, constraints of tumor, and OAR as mentioned above. Oncologist, radiographer, and medical physicist were all blinded from pre-brachytherapy MRI images and MRI based contours during CT planning. Afterwards, pre-brachytherapy MRI images were fused with planning CT by rigid registration using MIM Vista version 6.0.6 based on the geometry of applicator. MRI-based contours (HRCTV~mri~, IRCTV~mri~, bladder~mri~, rectum~mri~, and sigmoid~mri~) were then transferred to the CT images. HRCTV~mri~ D~90~, IRCTV~mri~ D~90~, bladder~mri~ D~2cc~, rectum~mri~ D~2cc~, and sigmoid~mri~ D~2cc~ of the CT-guided plans were compared with that of the MRI-guided plans.

Statistical methods {#sec2.6}
-------------------

Data were analyzed using the SPSS software version 18. Paired 2 tailed *t*-test was used to analyze data that were in normal distribution. Wilcoxon signed-rank test was used to analyze data otherwise. The differences in HRCTV~mri~ D~90~, IRCTV~mri~ D~90~, bladder~mri~ D~2cc~, rectum~mri~ D~2cc~, and sigmoid~mri~ D~2cc~ of CT-guided plans versus MRI-guided plans were compared. The patients whose HRCTV~mri~ D~90~ fulfilled planning constraint in both CT and MRI guided plans were selected, and the differences in OAR~mri~ D~2cc~ between the 2 plans were analyzed again. *P* values \< 0.05 were considered significant.

Results {#sec3}
=======

Between 1^st^ January 2016 and 28^th^ February 2017, 11 patients had MRI guided brachytherapy as mentioned above. The median patient age was 59, with a range of 28 to 66. Of the 11 patients, 1 (9.1%) had Fédération Internationale de Gynécologie et d'Obstetrique (FIGO) stage IIA, 5 (45.5%) had stage IIB, 2 (18.2%) had stage IIIA, and 3 (27.3%) had stage IIIB disease. Nine (81.8%) patients had squamous cell carcinoma, 2 (18.2%) had adenocarcinoma. The median treatment time was 49 days. Nine (81.8%) patients had WPI. Two (18.2%) patients, with contrast CT confirmed para-aortic lymph node metastases, received extended field radiotherapy with SIB (simultaneous-integrated boost). Ten (90.9%) patients received API 10 Gy in 5 fractions after WPI. All patients had concurrent cisplatin, with a median of 5 doses. Utrecht applicator (Nucletron, an Elekta company, Elekta AB, Stockholm, Sweden) was used in 10 (90.9%) patients, while multichannel was applied in the remaining patient. Interstitial needles were inserted in 8 (72.7%) patients, among which the median number of needles was 2 (range, 1 to 7).

[Table 2](#t0002){ref-type="table"} shows the comparison of HR-CTV dimensions and volumes between HRCTV~ct~ and HRCTV~mri~. There was statistically significant overestimation of width, thickness, and volume in HRCTV~ct~. The difference between height of HRCTV~ct~ and HRCTV~mri~ was not significant.

###### 

Comparison of high-risk clinical target volume (HR-CTV) dimensions and volumes between computed tomography-based and magnetic resonance imaging-based contouring

  Parameters       HRCTV~ct~[\*](#tf2-1){ref-type="table-fn"}   HRCTV~mri~[\*](#tf2-1){ref-type="table-fn"}   Mean difference between HRCTV~ct~ and HRCTV~mri~ [^\#^](#tf2-2){ref-type="table-fn"}   *p*
  ---------------- -------------------------------------------- --------------------------------------------- -------------------------------------------------------------------------------------- ------------
  Width (cm)       5.2 (0.9)                                    4.4 (1.0)                                     0.7 (0.3 to 1.2)                                                                       0.004
  Thickness (cm)   3.8 (0.6)                                    3.1 (0.7)                                     0.7 (0.3 to 1.1)                                                                       0.001
  Height (cm)      3.4 (1.0)                                    3.5 (1.0)                                     --0.2 (--0.6 to 0.2)                                                                   0.372 (NS)
  Volume (cm^3^)   50.7 (23.8)                                  33.2 (20.6)                                   17.5 (9.7 to 25.4)                                                                     0.001

HRCTV -- high-risk clinical target volume

Presented as mean (standard deviation)

Presented as mean (95% confidence interval)

The dosimetric differences of HRCTV~mri~ D~90~ and OAR~mri~ D~2cc~ between CT and MRI-guided plans were statistically insignificant ([Table 3](#t0003){ref-type="table"}). Four (36.4%) of the CT plans failed to achieve the HRCTV~mri~ D~90~ planning constraint, compared with 1 (9.1%) of that of MRI plans. Five (45.5%) of the CT plans had HRCTV~mri~ D~90~ higher than 8.3 Gy per fraction (extrapolated total dose to HRCTV~mri~ \> 95 Gy), while none of the MRI guided plans showed such overdose. With regard to EMBRACE, 1 (9.1%) of the plans in both modalities had bladder~mri~ D~2cc~ higher than constraint (7 Gy in the MRI plan, 6.8 Gy in the CT plan, from 2 different patients). One (9.1%) of the CT plans showed rectum~mri~ D~2cc~ of 5.6 Gy, which exceeded the constraint, compared with none in the MRI plans. No plans in either modality exceeded the constraint to sigmoid~mri~ D~2cc~. With regard to the stricter EMBRACE II protocol, 7 (63.6%) of the CT plans breached the aim for bladder~mri~ D~2cc~, compared with 2 (18.2%) of the MRI plans. Four (36.4%) of both CT and MRI plans showed overdose of rectum~mri~ D~2cc~. Three (27.3%) of both CT and MRI plans exceeded the aim for sigmoid~mri~ D~2cc~ ([Figure 1](#f0001){ref-type="fig"}).

###### 

Dosimetric differences of magnetic resonance imaging (MRI)-based targets and organs at risk between computed tomography (CT)-based and MRI-based planning

  Parameters            CT-guided plans[\*](#tf3-1){ref-type="table-fn"}   MRI-guided plans[\*](#tf3-1){ref-type="table-fn"}   Difference between CT-and MRI-guided plans[^\#^](#tf3-2){ref-type="table-fn"}   *p*
  --------------------- -------------------------------------------------- --------------------------------------------------- ------------------------------------------------------------------------------- ------------
  HRCTV~mri~ D~90~      8.1 (1.9) \[5.7-12.1\]                             7.8 (0.4) \[7-8.3\]                                 0.3 (--0.9 to 1.4)                                                              0.625 (NS)
  Bladder~mri~ D~2cc~   5.5 (0.9) \[3.3-6.8\]                              5.2 (0.8) \[4.0-7.0\]                               0.3 (--0.3 to 1.0)                                                              0.285 (NS)
  Rectum~mri~ D~2cc~    3.6 (1.1) \[1.6-5.6\]                              3.1 (1.1) \[2.1-4.9\]                               0.4 (--0.8 to 1.0)                                                              0.090 (NS)
  Sigmoid~mri~ D~2cc~   3.5 (1.2) \[1.5-4.9\]                              3.3 (1.4) \[1.1-4.7\]                               0.2 (--0.3 to 0.7)                                                              0.385 (NS)

HRCTV -- high-risk clinical target volume, D~90~ -- the percentage of the prescribed dose received by 90% volume of the prostate, D~2cc~ -- minimum dose to the most exposed 2 cm^3^

Dose per fraction of IGBT (Gy), presented as mean (standard deviation) \[range\]

Dose per fraction of IGBT (Gy), presented as mean (95% confidence interval)

![Percentage of patients achieving planning constraints and aims in computed tomography- versus magnetic resonance imaging-based planning](JCB-9-30887-g001){#f0001}

The dosimetric differences in OAR were analyzed again after exclusion of the four patients whose CT-guided plans failed to achieve the HRCTV D~90~ constraints ([Table 4](#t0004){ref-type="table"}). There was significant increase in OAR~mri~ D~2cc~ in CT plans, with the overall 95% CI range of 0.2 to 1.5 Gy per fraction. Extrapolating the results of one fraction to the whole course of IGBT, converted to EQD~2~ (α/β = 3 Gy) the 95% confidence interval of increase in bladder D~2cc~, rectum D~2cc~, and sigmoid D~2cc~ by planning with CT would be from 0.5 to 5.4 Gy, 0.8 to 4.9 Gy, and 0.5 to 2.8 Gy, respectively.

###### 

Dosimetric differences of organs at risk between computed tomography (CT)-based versus magnetic resonance imaging (MRI)-based planning, after exclusion of patients whose CT-based plans did not achieve HRCTV~mri~ D~90~ constraint

  Parameters            CT-guided plans[\*](#tf4-1){ref-type="table-fn"}   MRI-guided plans[\*](#tf4-1){ref-type="table-fn"}   Difference between CT- and MRI-guided plans[^\#^](#tf4-2){ref-type="table-fn"}   *p*
  --------------------- -------------------------------------------------- --------------------------------------------------- -------------------------------------------------------------------------------- -------
  Bladder~mri~ D~2cc~   5.9 (0.6)                                          5 (0.3)                                             0.9 (0.2 to 1.5)                                                                 0.018
  Rectum ~mri~ D~2cc~   3.6 (1.1)                                          2.8 (1.0)                                           0.9 (0.3 to 1.4)                                                                 0.009
  Sigmoid~mri~ D~2cc~   4.0 (1.0)                                          3.4 (1.1)                                           0.5 (0.2 to 0.9)                                                                 0.027

HRCTV -- high-risk clinical target volume, CT -- computed tomography, MRI -- magnetic resonance imaging, D~90~ -- the percentage of the prescribed dose received by 90% volume of the prostate, D~2cc~ -- minimum dose to the most exposed 2 cm^3^

Dose per fraction of IGBT (Gy), presented as mean (standard deviation)

Dose per fraction of IGBT (Gy), presented as mean (95% confidence interval)

Discussion {#sec4}
==========

This study is one of the few that have compared dose to actual targets (as represented by MRI contours) in CT versus MRI-guided brachytherapy. As opposed to past data showing statistically lower dose to HRCTV~ct~ D~90~ by CT planning compared with HRCTV~mri~ D~90~ by MRI planning, the current study shows no statistical difference in HRCTV~mri~ D~90~ between CT and MRI-guided plans. St-Amant *et al*. shows the same results in 5 patients with stage IB-IIB cervical cancer treated with intracavity brachytherapy without interstitial needle insertion \[[@cit0020]\]. However, the range of HRCTV~mri~ D~90~ in CT guided plans is excessively large (5.7 to 12.1). This can be explained by two possible case scenarios ([Figures 2A-B](#f0002){ref-type="fig"}). In [Figure 2A](#f0002){ref-type="fig"}, the HRCTV~mri~ falls into the high dose zone of the CT plan. During CT-guided planning, only the HRCTV~ct~ is known to oncologist and medical physicist. The IGBT plan is optimized to achieve the highest HRCTV~ct~ D~90~, limited by dose to OAR, which is the rectum in the example. The apparent HRCTV~ct~ D~90~ is less than 7 Gy, which fails to achieve the constraint. However, the HRCTV~mri~ D~90~ receives a much higher dose of more than 8.3 Gy. In [Figure 2B](#f0002){ref-type="fig"}, since the HRCTV~mri~ D~90~ falls into the dose gradient zone of the CT plan, the HRCTV~mri~ D~90~ is under-dosed. The real life examples of the scenarios are demonstrated in [Figures 3A](#f0003){ref-type="fig"} and [B](#f0003){ref-type="fig"}. In the present study, 4 out of 11 of CT-guided plans failed to achieve HRCTV~mri~ constraint. This is worrying since it correlates to inferior local control \[[@cit0004]\]. In fact, recently published data comparing MRI-guided versus CT-guided brachytherapy shows inferior overall survival for patients with CT-guided brachytherapy, which could possibly be explained by the results of the current study \[[@cit0021]\]. Five out of 11 of CT-guided plans had HRCTV~mri~ D~90~ higher than 8.3 Gy, extrapolated to total biological equivalent dose of more than 95 Gy. HRCTV D~90~ of 95 Gy already results in excellent tumor control, especially for small tumors, and further escalation of dose is not relevant \[[@cit0004]\], but could lead to increased dose to OAR. Only 18.2% of the CT-guided plans achieve an extrapolated dose of 85 to 95 Gy to HRCTV~mri~ D~90~. The gross uncertainties in CT-guided plans raise concern despite the statistical insignificant overall results. Further studies needs to be done to validate the insignificant results of current study. Studies to correlate patient, tumor, and treatment factors to the extent of dose uncertainties are also crucial to guide patient selection for MRI-guided planning in a resource limited setting.

![**A)** HRCTVmri falls into the high dose zone of the computed tomography (CT)-guided plan. Although the HRCTVct D90 is under-dosed, the actual target of interest, the HRCTVmri D90 receives more than 8.3 Gy. **B)** HRCTVmri falls into the dose gradient zone of the CT-guided plan. The HRCTVmri D90 is under-dosed](JCB-9-30887-g002){#f0002}

![**A)** Computed tomography (CT)-based plan of a patient with HRCTVct shown in blue and fused HRCTVmri shown in red. The width of the tumor is overestimated on CT, hence HRCTVmri falls into the high dose zone. The HRCTVct D90 is 7.9 Gy, but the dose delivered to the actual target, HRCTVmri D90, is 12.1 Gy. **B)** CT-based plan of another patient with HRCTVct shown in blue color and fused HRCTVmri shown in red color. Since the height of the tumor is underestimated on CT, HRCTVmri falls into the dose gradient zone. The HRCTVct D90 is 6.2 Gy, while HRCTVmri is 5.7 Gy](JCB-9-30887-g003){#f0003}

The present study demonstrates no overall differences in OAR~mri~ D~2cc~ between the two planning modalities. Subsequently, patients that failed to achieve HRCTV~mri~ D~90~ constraint in CT plans were excluded and analysis was repeated. This analysis is designed because the cases which failed to achieve HRCTV~mri~ D~90~ in CT plans are clearly inferior, further studies on the OAR D~2cc~, even if more favorable than MRI-guided plans (possibly due to geographical miss of targets), is not of importance. Among patients with HRCTV~mri~ D~90~ ≥ 7.2 Gy in CT plans, there is a statistical increase in OAR~mri~ D~2cc~. This indicates that even if CT plans fulfill the HRCTV constraints, there is a tendency to over-treat the OAR compared with MRI-guided planning.

Both EMBRACE and EMBRACE II protocols were used to analyze dose to OAR ([Table 1](#t0001){ref-type="table"}). Since medical physicist strictly observed the EMBRACE constraints, most treatment plans in either modality achieved the requirement. However, there were more CT plans breaching the EMBRACE II requirement than MRI, with more than 60% of those breaching the bladder planning aim. This bears clinical significance. Recent data have shown that the dose of rectum D~2cc~ correlates well with late rectal toxicities \[[@cit0019]\]. The EMBRACE II protocol also revealed the unpublished data from 680 patients, showing a significant dose-toxicity relationship at bladder D~2cc~ beyond 80 Gy, with significant increase in grade 2 or higher morbidities except ureter stenosis. The final results are awaited. The dose-toxicity relationship of sigmoid D~2cc~ is so far least established, but it is reasonable to assume characteristics similar to rectum until further data is available.

A major limitation of this study is the small sample size, given the short history of MRI-guided brachytherapy implementation in Hong Kong. Compared with 2D or CT-guided brachytherapy, MRI-based treatment involves longer time and higher financial costs, and requires intensive multi-disciplinary collaboration. Routine MRI-guided brachytherapy would remain a challenge in the years to come. Studies investigating in transrectal ultrasound or transabdominal ultrasound in combination with CT for target definition, has addressed the problem of resource limitation against utilization of MRI-planning. However, it is operator and equipment dependent, and statistically significant under-estimation of tumor thickness by transrectal ultrasound raises concern towards geographical miss \[[@cit0020], [@cit0022]\]. To facilitate better patient selection in the era of transition from CT- to MRI-guided planning, studies with a larger scale to delineate factors that predispose to over- or under-treatment of OARs and CTVs in CT-guided planning are eagerly awaited. Patients with high body mass index and those with larger cervical tumor involving parametrium at diagnosis with good response after external radiotherapy, show the greatest discrepancy between CT- and MRI-delineated HRCTV \[[@cit0007], [@cit0023]\]. This could be the direction for further studies.

There are no CT or MRI suites in the operation theatre (OT) in our center. Time is needed for patient transferal between the OT and the scanning rooms. It results in change in the anatomical positions of OARs, which are not fully correctable by image fusion based on the location of applicator ([Figure 4](#f0004){ref-type="fig"}). This could be a confounding factor in the difference between CT and MRI-guided plans.

![The computed tomography (CT)-based rectum is contoured in purple, while the fused magnetic resonance imaging (MRI)-based rectum is contoured in green. There is a change in the anatomical position of rectum between MRI and CT images, which can be a confounding factor for the dosimetric differences in the two planning modalities. The 4.9 Gy isodose line is shown in light-green, while the 3.9 Gy isodose line is shown in red. They correspond to the rectum D2cc dose constraint (EMBRACE) and aim (EMBRACE II), respectively](JCB-9-30887-g004){#f0004}

Conclusions {#sec5}
===========

MRI-guided IGBT remains the standard of care. CT-based planning could lead to an unrecognized under-dose of the actual treatment target or over-dose of the OARs, which could compromise the treatment response and worsen the toxicities. Further studies to illustrate the group of patients who would benefit the most from MRI-guided planning are eagerly awaited.
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